High-grade glioma mouse models and their applicability for preclinical testing

Area of Science:

• Neuro-oncology
• Cancer Biology
• Translational Medicine

Background:

• High-grade gliomas, including anaplastic astrocytoma (WHO grade III) and glioblastoma multiforme (WHO grade IV), are the most prevalent primary adult central nervous system tumors.
• Despite extensive research, high-grade gliomas remain highly lethal, necessitating the development of more effective therapies.
• Recent advances in understanding gliomagenesis have identified key genetic and molecular alterations, improving our fundamental knowledge of the disease.

Purpose of the Study:

• To review the current landscape of genetically engineered mouse models for high-grade gliomas.
• To critically evaluate the advantages and limitations of these models in preclinical settings.
• To assess their suitability for testing novel therapeutic strategies and drug regimens.

Main Methods:

• Literature review of established high-grade glioma mouse models.
• Analysis of genetic and molecular features of these models compared to human gliomas.
• Evaluation of preclinical data generated using these models for drug testing.

Main Results:

• Genetically engineered mouse models increasingly recapitulate human high-grade glioma heterogeneity and molecular profiles.
• These models offer valuable platforms for studying gliomagenesis and evaluating treatment responses.
• However, challenges remain in fully replicating the tumor microenvironment and clinical variability.

Conclusions:

• Established high-grade glioma mouse models are crucial tools for advancing preclinical drug development.
• Optimizing these models is essential for improving their predictive value in testing novel therapeutics.
• Further refinement will enhance their utility in accelerating the translation of research findings to clinical practice.